A similar finding to ours has also been reported for the potential FRDA therapeutic compound rhuEPO, where treatment of primary FRDA fibroblasts produced up to 2-fold increases in frataxin protein levels without any changes in FXN mRNA expression (Acquaviva et al., 2008). The gene discussed is FXN; the disease is Friedreich ataxia.